Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Feb 28;2(2):CD009327.
doi: 10.1002/14651858.CD009327.pub3.

Autologous serum eye drops for dry eye

Qing Pan  1   2 , Adla Angelina  3 , Michael Marrone  4 , Walter J Stark  2 , Esen K Akpek  2
Affiliations
Meta-Analysis

Autologous serum eye drops for dry eye

Qing Pan et al. Cochrane Database Syst Rev. .

Abstract

Background: Theoretically, autologous serum eye drops (AS) offer a potential advantage over traditional therapies on the assumption that AS not only serve as a lacrimal substitute to provide lubrication but contain other biochemical components that allow them to mimic natural tears more closely. Application of AS has gained popularity as second-line therapy for patients with dry eye. Published studies on this subject indicate that autologous serum could be an effective treatment for dry eye.

Objectives: We conducted this review to evaluate the efficacy and safety of AS given alone or in combination with artificial tears as compared with artificial tears alone, saline, placebo, or no treatment for adults with dry eye.

Search methods: We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 5), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to July 2016), Embase (January 1980 to July 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to July 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We also searched the Science Citation Index Expanded database (December 2016) and reference lists of included studies. We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 5 July 2016.

Selection criteria: We included randomized controlled trials (RCTs) that compared AS versus artificial tears for treatment of adults with dry eye.

Data collection and analysis: Two review authors independently screened all titles and abstracts and assessed full-text reports of potentially eligible trials. Two review authors extracted data and assessed risk of bias and characteristics of included trials. We contacted investigators to ask for missing data. For both primary and secondary outcomes, we reported mean differences with corresponding 95% confidence intervals (CIs) for continuous outcomes. We did not perform meta-analysis owing to differences in outcome assessments across trials.

Main results: We identified five eligible RCTs (92 participants) that compared AS versus artificial tears or saline in individuals with dry eye of various origins (Sjögren's syndrome-related dry eye, non-Sjögren's syndrome dry eye, and postoperative dry eye induced by laser-assisted in situ keratomileusis (LASIK)). We assessed the certainty of evidence as low or very low because of lack of reporting of quantitative data for most outcomes and unclear or high risk of bias among trials. We judged most risk of bias domains to have unclear risk in two trials owing to insufficient reporting of trial characteristics, and we considered one trial to have high risk of bias for most domains. We judged the remaining two trials to have low risk of bias; however, these trials used a cross-over design and did not report data in a way that could be used to compare outcomes between treatment groups appropriately. Incomplete outcome reporting and heterogeneity among outcomes and follow-up periods prevented inclusion of these trials in a summary meta-analysis.Three trials compared AS with artificial tears; however, only one trial reported quantitative data for analysis. Low-certainty evidence from one trial suggested that AS might provide some improvement in participant-reported symptoms compared with artificial tears after two weeks of treatment; the mean difference in mean change in symptom score measured on a visual analogue scale (range 0 to 100, with higher scores representing worse symptoms) was -12.0 (95% confidence interval (CI) -20.16 to -3.84; 20 participants). This same trial found mixed results with respect to ocular surface outcomes; the mean difference in mean change in scores between AS and artificial tears was -0.9 (95% CI -1.47 to -0.33; 20 participants; low-certainty evidence) for fluorescein staining and -2.2 (95% CI -2.73 to -1.67; 20 participants; low-certainty evidence) for Rose Bengal staining. Both staining scales range from 0 to 9, with higher scores indicating worse results. The mean change in tear film break-up time was 2.00 seconds longer (95% CI 0.99 to 3.01; 20 participants; low-certainty evidence) in the AS group than in the artificial tears group. Investigators reported no clinically meaningful differences in Schirmer's test scores between groups (mean difference -0.40 mm, 95% CI -2.91 to 2.11; 20 participants; low-certainty evidence). None of these three trials reported tear hyperosmolarity and adverse events.Two trials compared AS versus saline; however, only one trial reported quantitative data for analysis of only one outcome (Rose Bengal staining). Trial investigators of the two studies reported no differences in symptom scores, fluorescein staining scores, tear film break-up times, or Schirmer's test scores between groups at two to four weeks' follow-up. Very low-certainty evidence from one trial suggested that AS might provide some improvement in Rose Bengal staining scores compared with saline after four weeks of treatment; the mean difference in Rose Bengal staining score (range from 0 to 9, with higher scores showing worse results) was -0.60 (95% CI -1.11 to -0.09; 35 participants). Neither trial reported tear hyperosmolarity outcomes. One trial reported adverse events; two of 12 participants had signs of conjunctivitis with negative culture that did resolve.

Authors' conclusions: Overall, investigators reported inconsistency in possible benefits of AS for improving participant-reported symptoms and other objective clinical measures. There might be some benefit in symptoms with AS compared with artificial tears in the short-term, but we found no evidence of an effect after two weeks of treatment. Well-planned, large, high-quality RCTs are warranted to examine participants with dry eye of different severities by using standardized questionnaires to measure participant-reported outcomes, as well as objective clinical tests and objective biomarkers to assess the benefit of AS therapy for dry eye.

PubMed Disclaimer

Conflict of interest statement

QP: none known. AA: none known. MM: none known. WJS: none known. EKA: none known.

Figures

1
1
Results obtained by searching for studies for inclusion in the review.
2
2
Methodological quality summary: risk of bias review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Autologous serum (20%) versus artificial tears, Outcome 1 Participant‐reported symptoms (severe dry eye).
1.2
1.2. Analysis
Comparison 1 Autologous serum (20%) versus artificial tears, Outcome 2 Fluorescein (severe dry eye).
1.3
1.3. Analysis
Comparison 1 Autologous serum (20%) versus artificial tears, Outcome 3 Rose Bengal (severe dry eye).
1.4
1.4. Analysis
Comparison 1 Autologous serum (20%) versus artificial tears, Outcome 4 TBUT (severe dry eye).
1.5
1.5. Analysis
Comparison 1 Autologous serum (20%) versus artificial tears, Outcome 5 Schirmer's 1 test (severe dry eye).
2.1
2.1. Analysis
Comparison 2 Autologous serum (20%) versus saline solution, Outcome 1 Rose Bengal (post‐LASIK dry eye).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Celebi 2014 {published data only}
    1. Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double‐blind crossover study. Graefes Archives of Clinical and Experimental Ophthalmology 2014;252(4):619‐26. - PubMed
Kojima 2005a {published data only}
    1. Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case‐control study. American Journal Ophthalmology 2005;139(2):242‐6. - PubMed
    1. Kojima T, Ishida R, Goto E, Matsumoto Y, Dogru M, Tsubota K. The efficacy of autologous serum eye drops for Keratoconjunctivitis Sicca ‐ a prospective study. Investigative Ophthalmology and Visual Science 2004;45:ARVO E‐abstract 3894.
Noda‐Tsuruya 2006 {published data only}
    1. Noda‐Tsuruya T, Asano‐Kato N, Toda I, Tsubota K. Autologous serum eye drops for dry eye after LASIK. Journal of Refractive Surgery 2006;22(1):61‐6. - PubMed
Tananuvat 2001 {published data only}
    1. Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea 2001;20(8):802–6. - PubMed
Urzua 2012 {published data only}
    1. Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double‐blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Current Eye Research 2012;37(8):684‐8. - PubMed

References to studies excluded from this review

Albegger 1972 {published data only}
    1. Albegger KW, Tilz GP. Sjogren's syndrome and its therapy. A therapeutic attempt using antilymphocyte serum [Zum Sjogren‐syndrom und seiner behandlung. Ein therapieversuch mit antilymphozytenglobulin]. Zeitschrift Fur Laryngologie, Rhinologie, Otologie Und Ihre Grenzgebiete 1972;51(7):429‐37. - PubMed
Alvarado 2004 {published data only}
    1. Alvarado Valero MC, Martinez Toldos JJ, Borras Blasco J, Alminana Alminana A, Perez Ramos JM. Treatment of persistent epithelial defects using autologous serum application [Tratamiento de defectos epiteliales persistentes mediante suero autologo]. Archivos De La Sociedad Espanola De Oftalmologia 2004;79(11):537‐42. - PubMed
Anderson 2004 {published data only}
    1. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Current Opinion in Ophthalmology 2004;15(6):503‐7. - PubMed
Badami 2009 {published data only}
    1. Badami K, McKellar M. Allogeneic serum eye drops ‐ a useful alternative for those unable to be autologous donors. Transfusion. Proceedings of the AABB Annual Meeting and TXPO; 2009 Oct 24 ‐27; New Orleans (LA). 2009.
Bradley 2008 {published data only}
    1. Bradley JC, Bradley RH, Mccartney DL, Mannis MJ. Serum growth factor analysis in dry eye syndrome. Clinical and Experimental Ophthalmology 2008;36(8):717‐20. - PubMed
Brown 2005 {published data only}
    1. Brown SM, Bradley JC. The effect of autologous serum eye drops in the treatment of severe dry eye disease: a prospective randomized case‐control study. American Journal of Ophthalmology 2005;140(3):565. - PubMed
Chiang 2007 {published data only}
    1. Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft‐versus‐host disease. Cornea 2007;26(7):861‐3. - PubMed
Craig 2008 {published data only}
    1. Craig JP. A natural solution to dry eye?. Clinical and Experimental Ophthalmology 2008;36(2):109‐10. - PubMed
Fea 2016 {published data only}
    1. Fea AM, Aragno V, Testa V, Machetta F, Parisi S, D'Antico S, et al. The effect of autologous platelet lysate eye drops: an in vivo confocal microscopy study. BioMed Research International 2016;2016:8406832. - PMC - PubMed
Fuchsluger 2005 {published data only}
    1. Fuchsluger TA, Steuhl KP, Meller D. Neurotrophic keratopathy ‐ a post‐LASIK case report. Klinische Monatsblatter fur Augenheilkunde 2005;222(11):901‐4. - PubMed
Geerling 2002 {published data only}
    1. Geerling G, Hartwig D. Autologous serum‐eye‐drops for ocular surface disorders. A literature review and recommendations for their application [Autologe serum‐augentropfen zur therapie der augenoberflache eine ubersicht zur wirksamkeit und empfehlungen zur anwendung]. Ophthalmologe 2002;99(12):949‐59. - PubMed
Geerling 2004 {published data only}
    1. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. British Journal of Ophthalmology 2004;88(11):1467‐74. - PMC - PubMed
Geerling 2008 {published data only}
    1. Geerling G, Unterlauft JD, Kasper K, Schrader S, Opitz A, Hartwig D. Autologous serum and alternative blood products for the treatment of ocular surface disorders [Eigenserum und alternative Blutprodukte zur Behandlung von Augenoberflachenerkrankungen]. Ophthalmologe 2008;105(7):623‐31. - PubMed
Harritshoj 2011 {unpublished data only}
    1. Harritshoj LH, Hansen MB, Julian HO. Ready‐made allogenic serum eye drops for severe dry eye disease. Vox Sanguinis. Proceedings of the 21st Regional Congress of the International Society of Blood Transfusion; 2011 Jun 18‐22; Lisbon, Portugal. 2011.
Hwang 2014 {published data only}
    1. Hwang J, Chung SH, Jeon S, Kwok SK, Park SH, Kim MS. Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary sjogren syndrome. Cornea 2014;33:663‐7. - PubMed
Hyon 2007 {published data only}
    1. Hyon JY, Lee YJ, Yun PY. Management of ocular surface inflammation in Sjogren syndrome. Cornea 2007;26(9 Suppl 1):S13‐5. - PubMed
Jaksche 2005 {unpublished data only}
    1. Jaksche A, Sbeity Z, Domeier E, Fimmers R, Holz F, Loeffler KU. Undiluted versus diluted autologous serum eye drops (ASED): a prospective, randomized, double‐blind study in patients with refractory dry eye‐syndrome. Investigative Ophthalmology and Visual Science 2005;46:ARVO E‐abstract 2045.
Koffler 2006 {published data only}
    1. Koffler BH. Autologous serum therapy of the ocular surface with novel delivery by platelet concentrate gel. Ocular Surface 2006;4(4):188‐95. - PubMed
Kojima 2005b {published data only}
    1. Kojima T, Dogru M, Matsumoto Y, Goto E, Tsubota K. Tear film and ocular surface abnormalities after eyelid tattooing. Ophthalmic Plastic and Reconstructive Surgery 2005;21(1):69‐71. - PubMed
Kojima 2008 {published data only}
    1. Kojima T, Higuchi A, Goto E, Matsumoto Y, Dogru M, Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea 2008;27(Suppl 1):25‐30. - PubMed
Li 2015 {published data only}
    1. Li J, Zhang X, Zheng Q, Zhu Y, Wang H, Ma H, et al. Comparative evaluation of silicone hydrogel contact lenses and autologous serum for management of Sjogren syndrome‐associated dry eye. Cornea 2015;34(9):1072‐8. - PubMed
Messmer 2005 {published data only}
    1. Messmer EM. Management of keratoconjunctivitis sicca in Sjogren's syndrome. Aktuelle Rheumatologie 2005;30(1):59‐65.
Movahedan 2006 {published data only}
    1. Movahedan H, Ghassemifar V. Treatment of persistent corneal epithelial defect with autologous serum. Asian Journal of Ophthalmology 2006;8(6):236‐41.
Mukhopadhyay 2015 {published data only}
    1. Mukhopadhyay S, Sen S, Datta H. Comparative role of 20% cord blood serum and 20% autologous serum in dry eye associated with Hansen's disease: a tear proteomic study. British Journal of Ophthalmology 2015;99(1):108‐12. - PubMed
NCT02752763 {published data only}
    1. NCT02752763. Comparison of autologous serum versus preservative free artificial tear. clinicaltrials.gov/ct2/show/NCT02752763 (accessed 13 December 2016).
Noble 2004 {published data only}
    1. Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. British Journal of Ophthalmology 2004;88(5):647–52. - PMC - PubMed
Ogawa 2003 {published data only}
    1. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft‐versus‐host disease. Bone Marrow Transplantation 2003;31(7):579‐83. - PubMed
Poon 2001 {published data only}
    1. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. British Journal of Ophthalmology 2001;85(10):1188‐97. - PMC - PubMed
Watson 2010 {published data only}
    1. Watson S L, Daniels JT, Geerling G, Dart JK. Clinical trials of therapeutic ocular surface medium for moderate to severe dry eye. Cornea 2010;29(11):1241‐6. - PubMed
Yoon 2007 {published data only}
    1. Yoon KC, Heo H, Im SK, You IC, Kim YH, Park YG. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. American Journal of Ophthalmology 2007;144(1):86‐92. - PubMed

Additional references

AAO 2011
    1. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practive Pattern Guidlines. Dry Eye Syndrome ‐ Limited Revision. American Academy of Ophtalmology. www.aao.org/ppp (accessed 13 March 2012).
Akpek 2011
    1. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnel PJ. Treatment of Sjögren's Syndrome‐associated dry eye. Ophthalmology 2011;118:1242‐52. - PubMed
Alfonso 1999
    1. Afonso AA, Monroy D, Stern ME, Feuer WJ, Tseng SC, Pflugfelder SC. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 1999;106(4):803‐10. - PubMed
Baudouin 2001
    1. Baudouin C. The pathology of dry eye. Survey of Ophthalmology 2001;45(Suppl 2):S211‐20. - PubMed
Baudouin 2010
    1. Baoudouin C, Labbe A, Liang H, Pauly A, Brignole‐Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Progress in Retinal and Eye Research 2010;29(4):321‐34. - PubMed
Begley 2003
    1. Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, et al. The relationship between habitual patient‐reported symptoms and clinical signs among patients with dry eye of varying severity. Investigative Ophthalmology and Visual Science 2003;44(11):4753‐61. - PubMed
Behrens 2006
    1. Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006;25(8):900‐7. - PubMed
Blomquist 2010
    1. Blomquist PH. Ocular complications of systemic medications. American Journal of Medical Science 2011; Vol. 342, issue 1:62‐9. - PubMed
Bron 2003
    1. Bron A, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22(7):640‐50. - PubMed
Campos 1992
    1. Campos M, Hertzog L, Garbus JJ, McDonnell PJ. Corneal sensitivity after photorefractive keratectomy. American Journal of Ophthalmology 1992;114(1):51‐4. - PubMed
Chambers 1999
    1. Chambers CT, Giesbreacht K, Craig KD, Bennett SM, Huntsman E. A comparison of faces scales for the measurement of pediatric pain: children's and parent's ratings. Pain 1999;83(1):25‐35. - PubMed
Chodosh 1994
    1. Chodosh J, Dix RD, Howell RC, Stroop WG, Tseng SC. Staining characteristics and antiviral activities of sulforhodamine B and lissamine green. Investigative Ophthalmology and Vision Science 1994;35(3):1046‐58. - PubMed
de Paiva 2008
    1. Paiva CS, Pflugfelder SC. Rational for anti‐inflammatory therapy in dry eye syndrome. Arquivos Brasileiros de Oftalmolgia 2008;71(Suppl 6):89‐95. - PubMed
Demato 1984
    1. Demato BE, Allan D, Murray SB, Lee WR. Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease. British Journal of Ophthalmology 1984;68(9):674‐80. - PMC - PubMed
DEWS 2007
    1. Anonymous. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocular Surface 2007;5(2):75‐92. - PubMed
Dogru 2011
    1. Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opinion on Pharmacotherapy 2011;12(3):325‐34. - PubMed
Doughty 1997
    1. Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optometry and Vision Science 1997;74(8):624‐31. - PubMed
Ervin 2010
    1. Ervin A‐M, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD006775.pub2] - DOI - PMC - PubMed
Foulks 2003
    1. Foulks GN. The evolving treatment of dry eye. Ophthalmology Clinics of North America 2003;16(1):29‐35. - PubMed
Fox 1984
    1. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis and Rheumatism 1984;27(2):459‐61. - PubMed
Fox 2006
    1. Fox RI, Liu AY. Sjogren's syndrome in dermatology. Clinics in Dermatology 2006;24(5):393‐413. - PubMed
Fuentes‐Paez 2011
    1. Fuentes‐Paez G, Herreras JM, Cordero Y, Almaraz A, Gonxalez MJ, Calonge M. Lack of concordance between dry eye syndrome questionnaires and diagnostic tests [Falta de concordancia entre los cuestionarios y las pruebas diagnosticas en el sindrome de ojo seco]. Archivos de la Sociedad Espanola de Oftalmologia 2011;86(1):3‐7. - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6. - PMC - PubMed
Gordon 1995
    1. Gordon JF, Johnson P, Musch DC. Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. American Journal of Ophthalmology 1995;119(3):281‐7. - PubMed
GRADEpro 2014 [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro. Version accessed 13 December 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org.
Higgins 2011b
    1. Higgins JP, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org.
Imanishi 2000
    1. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozone C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Progress in Retinal and Eye Research 2000;19(1):113‐29. - PubMed
Joh 1986
    1. Joh T, Itoh M, Katsumi K, Yokoyama Y, Takeuchi T, Kato T, et al. Physiological concentrations of human epidermal growth factor in biological fluids: use of a sensitive enzyme immunoassay. Clinica Chima Acta 1986;158(1):81‐90. - PubMed
Kumar 2005
    1. Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic Basis of Disease. 7th Edition. Philadelphia: Elsevier Saunders, 2005.
Langnado 2004
    1. Lagnado R, King AJ, Donald F, Dua HS. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. British Journal of Ophthalmology 2004;88(4):464‐5. - PMC - PubMed
Lee 2008
    1. Lee GA, Chen SX. Autologous serum in the management of recalcitrant dry eye syndrome. Clinical and Experimental Ophthalmology 2008;36(2):119‐22. - PubMed
Lemp 1995
    1. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. The CLAO Journal 1995;21(4):221‐32. - PubMed
Lemp 2008
    1. Lemp MA. Management of dry eye disease. American Journal of Managed Care 2008;14(Suppl 3):S88‐101. - PubMed
Lemp 2011
    1. Lemp MA, Bron AJ, Baudouin C, Benitez del Castillo JM, Geffen D, Tauber J, et al. Tear osmolarity in the diagnosis and management of dry eye disease. American Journal of Ophthalmology 2001;151(5):792‐8. - PubMed
Lin 2003
    1. Lin PY, Tsai SY, Cheng CY, Liu JH, Chou P, Hsu WM. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology 2003;110(6):1096‐101. - PubMed
Liu 2005
    1. Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimised protocol for the production of autologous serum eyedrops. Graefe's Archive for Clinical and Experimental Ophthalmology 2005;243(7):706‐14. - PubMed
Marci 2000
    1. Marci A, Pflugfelder S. Correlation of the Schirmer 1 and fluorescein clearance tests with the severity of corneal epithelia and eyelid disease. Archives of Ophthalmology 2000;118(12):1632‐38. - PubMed
Matsumoto 2004
    1. Matsumoto Y, Dogrou M, Goto E, Ohashi Y, Kojima T, Ishida R, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology 2004;111(6):1115‐20. - PubMed
McCarty 1998
    1. McCarty C, Bansal AK, Liningston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998;105(6):1114‐9. - PubMed
McCluskey 1987
    1. McCluskey P, Wakefield D, York L. Topical fibronectin therapy in persistent corneal ulceration. Australia and New Zealand Journal of Ophthalmology 1987;15(4):257‐62. - PubMed
McDonnell 1988
    1. McDonnell PJ, Schanzlin DJ, Rao NA. Immunoglobulin deposition in the cornea after application of autologous serum. Archives of Ophthalmology 1988;106(10):1423‐5. - PubMed
Meadows 2005
    1. Meadows M. Dealing with dry eye. FDA Consumer Magazine 2005; Vol. 39, issue 3. - PubMed
Nelson 1988
    1. Nelson JD, Farris RL. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. A comparison in patients with keratoconjunctivitis sicca. Archives of Ophthalmology 1988;106:484‐7. - PubMed
Nelson 1992
    1. Nelson JD, Gordon JF. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group. American Journal of Ophthalmology 1992;114(4):441‐7. - PubMed
Nichols 2004
    1. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea 2004;23(3):272‐85. - PubMed
Nishida 1983
    1. Nishia T, Ohasai Y, Awata T, Manabe R. Fibronectin. A new therapy for corneal trophic ulcer. Archives of Ophthalmology 1983;101(7):1046‐8. - PubMed
Nishida 1987
    1. Nishida T, Nakamura M, Ofuji K, Reid TW, Mannis MJ, Murphy CJ. Synergistic effects of substance P with insulin‐like growth factor‐1 on epithelia migration of the cornea. Journal of Cell Physiology 1996;169(1):156‐66. - PubMed
Ozcura 2007
    1. Ozcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome. Ocular Immunology and Inflammation 2007;15(5):389‐93. - PubMed
Pancholi 1998
    1. Pancholi S, Tullo A, Khaliq A, Foreman D, Boulton M. The effects of growth factors and conditioned media on the proliferation of human corneal epithelial cells and keratocytes. Graefe's Archive for Clinical and Experimental Ophthalmology 1998;236(1):1‐8. - PubMed
Partal 2011
    1. Partal A, Scott E. Low‐cost protocol for the production of autologous serum eye drops by blood collection and processing centres for the treatment of ocular surface disease. Transfusion Medicine 2011; Vol. 21, issue 4:271‐7. - PubMed
Patel 2002
    1. Patel SJ, Lundy DC. Ocular manifestations of autoimmune disease. American Family Physician 2002;66(6):991‐8. - PubMed
Patrick 2011
    1. Patrick D, Guyatt GH, Acquardro C. Chapter 17: Patient‐reported outcomes. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org.
Perry 2004
    1. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Current Opinion in Ophthalmology 2004;15(4):299‐304. - PubMed
Pflugfelder 2004
    1. Pfludgfelder SC. Antiinflammatory therapy for dry eye. American Journal of Ophthalmology 2004;137(2):337‐42. - PubMed
Phan 1987
    1. Phan TM, Foster CE, Bourochoff SA, Zagachin LM, Colvin RB. Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers. American Journal of Ophthalmology 1987;104(5):494‐501. - PubMed
Phasukkijwatana 2011
    1. Phasukkijwatana N, Lertrit P, Liammongkolkul S, Prabhasawat P. Stability of epitheliotrophic factors in autologous serum eye drops from chronic Stevens‐Johnson syndrome dry eye compared to non‐autoimmune dry eye. Current Eye Research 2011;36(9):775‐81. - PubMed
Pucker 2016
    1. Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD009729.pub2] - DOI - PMC - PubMed
Quinto 2008
    1. Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface disease. Arguivos Brasileiros de Oftalmologia 2008;71(Suppl 6):47‐54. - PubMed
Ralph 1975
    1. Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Archives of Ophthalmology 1975;93(10):1039‐43. - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roback 2008
    1. Roback JD, Coombs MR, Grossman BJ, Hillyer CD. Technical Manual. 16th Edition. Bethesda, MD: American Association of Blood Banks, 2008.
Rocha 2000
    1. Rocha EM, Pelegrino FS, Paiva CS, Vigorito AC, Sourza CA. GVHD dry eye treated with autologous serum tears. Bone Marrow Transplant 2000;25(10):1101‐3. - PubMed
Sall 2000
    1. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 43 Study Group. Ophthalmology 2000;107(4):631‐9. - PubMed
Schaumberg 2003
    1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Ophthalmology 2003;136(2):318‐26. - PubMed
Schein 1997
    1. Schein OD, Tielsch JM, Munõz B, Bandeen‐Roche K, West S. Relation between signs and symptoms of dry eye in the elderly. A population‐based perspective. Ophthalmology 1997;104(9):1395‐401. - PubMed
Stern 2004
    1. Stern ME, Gao J, Siemasko KF, Beurerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Experimental Eye Research 2004;78(3):409‐16. - PubMed
Stevenson 2000
    1. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate‐to‐severe dry eye disease: a dose‐ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107(5):967‐74. - PubMed
Toda 2004
    1. Toda I, Asano‐Kato N, Hori‐Komai Y, Tsubota K. Ocular surface treatment before last in situ keratomileusis in patients with severe dry eye. Journal of Refractive Surgery 2004;20(3):270‐5. - PubMed
Toker 2010
    1. Toker E, Asfuroglu E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea 2010;29(2):133‐40. - PubMed
Tomlinson 2006
    1. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Investigative Ophthalmology and Visual Science 2006;47(10):4309‐15. - PubMed
Tomlinson 2009
    1. Tomlinson A, McCann L, Pearce EI. Comparison of OcuSense and Clifton Nanolitre Osmometers. Investigative Ophthalmology and Vision Science 2009;50:ARVO E‐abstract 534.
Tsubota 1996
    1. Tsubota K, Satake Y, Ohyama M, Toda I, Takano Y, Ono M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens‐Johnson syndrome. American Journal of Ophthalmology 1996;122(1):38‐52. - PubMed
Tsubota 1999
    1. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, et al. Treatment of dry eye by autologous serum applications in Sjögren's syndrome. British Journal of Ophthalmology 1999;83(4):390‐5. - PMC - PubMed
Tsubota 2000
    1. Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. International Ophthalmology Clinics 2000;40(4):113‐122. - PubMed
Versura 2012
    1. Versura P, Profazio V, Buzzi M, Stancari A, Arpinati M, Malavolta N, et al. Efficacy of standardized and quality‐controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea 2012;32(4):412‐8. - PubMed
Viso 2012
    1. Viso E, Rodriguez‐Ares MT, Abelenda D, Oubina B, Gude F. Prevalence of asymptomatic and symptomatic meibomian glad dysfunction in the general population of Spain. Investigative Ophthalmology and Visual Science 2012;53(6):2601‐6. - PubMed
Wilson 2007
    1. Wilson SE, Perry HD. Long‐term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007;114(1):76‐9. - PubMed
Yamada 1990
    1. Yamada K, Hayasaka S, Setogawa T. Test results in patients with Sjogren's syndrome defined by the Japanese criteria. Acta Ophthalmogica 1990;68(1):80‐6. - PubMed

References to other published versions of this review

Pan 2011
    1. Pan Q, Angelina A, Marrone M, Daoud Y, Stark WJ, Heflin T, et al. Autologous serum eye drops for dry eye syndrome. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD009327] - DOI
Pan 2013
    1. Pan Q, Angelina A, Zambrano A, Marrone M, Stark WJ, Heflin T, et al. Autologous serum eye drops for dry eye. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD009327.pub2] - DOI - PMC - PubMed

Publication types

LinkOut - more resources